Investigational Drug Information for INCB039110
✉ Email this page to a colleague
What is the development status for investigational drug INCB039110?
INCB039110 is an investigational drug.
There have been 44 clinical trials for INCB039110.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 19th 2017.
The most common disease conditions in clinical trials are Graft vs Host Disease, Primary Myelofibrosis, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are seventy US patents protecting this investigational drug and one international patent.
Summary for INCB039110
| US Patents | 70 |
| International Patents | 1,208 |
| US Patent Applications | 397 |
| WIPO Patent Applications | 277 |
| Japanese Patent Applications | 85 |
| Clinical Trial Progress | Phase 3 (2017-07-19) |
| Vendors | 46 |
Recent Clinical Trials for INCB039110
| Title | Sponsor | Phase |
|---|---|---|
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Incyte Corporation | Phase 1 |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for INCB039110
Top disease conditions for INCB039110
Top clinical trial sponsors for INCB039110
US Patents for INCB039110
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INCB039110 | ⤷ Try a Trial | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
| INCB039110 | ⤷ Try a Trial | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Try a Trial |
| INCB039110 | ⤷ Try a Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INCB039110
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INCB039110 | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Try a Trial |
| INCB039110 | Argentina | AR096246 | 2033-05-09 | ⤷ Try a Trial |
| INCB039110 | Australia | AU2014262622 | 2033-05-09 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
